Originally published by our sister publication Infectious Disease Special Edition
By Marie Rosenthal, MS
The Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend pneumococcal 21-valent conjugate vaccine (PCV21; Capvaxive, Merck) as an option for adults 65 years of age and older, as well as adults 19 and older with certain chronic conditions.
Specifically, the ACIP voted to recommend a single dose of PCV21 for:
- adults 65 years of age and older who have not received a